AstraZeneca's breast cancer drug fails in late-stage trial

AstraZeneca's breast cancer drug failed to meet the main ‌goal of ⁠improving ⁠progression-free survival during a late-stage trial, it said on Friday, marking a setback for the recently approved treatment.

U.S.-listed shares of ​AstraZeneca fell 3% ⁠in aftermarket trading.

The ‌drug, branded as Etcamah, when tested ⁠in combination with another cancer treatment palbociclib, only showed a numerical improvement in previously untreated patients with a form of advanced breast cancer, the company said.


Read more: AstraZeneca 'magic' faces rare test after trial failure, share slide

AstraZeneca said ‌the trial data will be shared in ​due course.

Last week, the ⁠U.S. Food and Drug Administration gave accelerated approval for Etcamah to be used together with certain targeted cancer medicines known as CDK4/6 inhibitor.